

Anti-ANG2 & VEGFA Antibody (Vanucizumab)

Introduction

Vanucizumab is a first-in-class bispecific IgG1 monoclonal antibody that simultaneously blocks the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their receptors. Vanucizumab has anti-angiogenic and anti-cancer effects.

Product parameters

Alternative Names	RO-5520985, RG-7221, B800Z06O8K
Target Accession	Q9UID3 & P15692
Target	ANG2 & VEGFA
CAS number	1448221-05-3
Molecular Weight	146.89 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human VEGF165 His at 2 ug/mL can bind Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab), EC50=0.0124 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

